Protara Therapeutics
TARA
22 hedge funds and large institutions have $98.8M invested in Protara Therapeutics in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
13% more capital invested
Capital invested by funds: $87.8M → $98.8M (+$11M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less funds holding
Funds holding: 24 → 22 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$168K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$130K |
| 3 |
PPCM
Pillar Pacific Capital Management
Pacifica,
California
|
+$126K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$110K |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$10.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$481K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$132K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$89K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12K |
| 5 |
Morgan Stanley
New York
|
-$2.19K |
TARA Hedge Fund Activity: Q1 2015 in Review
22 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2015, worth a combined $98.8M — up 13% from $87.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TARA and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $168K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $481K sold.
- 22 institutional investors held Protara Therapeutics (TARA) as of Q1 2015, down from 24 in Q4 2014.
- Funds reported $98.8M of Protara Therapeutics stock for Q1 2015, up 13% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q1 2015 and 5 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q1 2015 was Vanguard Group, an estimated $168K added.
- The largest Protara Therapeutics seller in Q1 2015 was Alyeska Investment Group, an estimated $481K sold.
Based on aggregated 13F filings for Q1 2015.